Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPKopen access
- Authors
- Oh, Yoo Jin; Kim, Hye Young; Lee, Mi Hwa; Suh, Sung Hwan; Choi, Yongmun; Nam, Tae-gyu; Kwon, Woo Young; Lee, Sang Yeob; Yoo, Young Hyun
- Issue Date
- Dec-2018
- Publisher
- AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
- Keywords
- NONALCOHOLIC FATTY LIVER; ADIPOSE-TISSUE; IN-VITRO; INSULIN; DISEASE; STEATOHEPATITIS; INFLAMMATION; PROTEIN; ACTIVATION; INHIBITOR
- Citation
- MOLECULAR PHARMACOLOGY, v.94, no.6, pp.1401 - 1411
- Indexed
- SCIE
SCOPUS
- Journal Title
- MOLECULAR PHARMACOLOGY
- Volume
- 94
- Number
- 6
- Start Page
- 1401
- End Page
- 1411
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/4724
- DOI
- 10.1124/mol.118.113217
- ISSN
- 0026-895X
- Abstract
- Nonalcoholic fatty liver disease (NAFLD) is an increasingly studied condition that can progress to end-stage liver disease. Although NAFLD was first described in 1980, a complete understanding of the mechanism and causes of this disease is still lacking. Six-transmembrane protein of prostate 2 (STAMP2) plays a role in integrating inflammatory and nutritional signals with metabolism. Our previous study suggested that STAMP2 may be a suitable target for treating NAFLD. In the current study, we performed a focused drug-screening and found that cilostazol could be a potential STAMP2 enhancer. Thus, we examined whether cilostazol alleviates NAFLD through STAMP2. The in vivo and in vitro pharmacological efficacies of cilostazol on STAMP2 expression and lipid accumulation were analyzed in NAFLD mice induced by high-fat diet (HFD) and in HepG2 cell lines treated by oleic acid (OA), respectively. Cilostazol increased the expression of STAMP2 through transcriptional regulation in vivo and in vitro. Cilostazol also dampened the STAMP2 downregulation caused by the HFD and by OA in vivo and in vitro, respectively. Cilostazol activated AMP-activated protein kinase (AMPK) in vivo and in vitro, and AMPK functions upstream of STAMP2, and reversed downregulation of STAMP2 expression through AMPK in the NAFLD model. Cilostazol ameliorates hepatic steatosis by enhancing hepatic STAMP2 expression through AMPK. Enhancing STAMP2 expression with cilostazol represents a potential therapeutic avenue for treatment of NAFLD.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/4724)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.